Bright Minds Biosciences Inc. (DRUG)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 45/100 (MEDIUM), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: ?% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Bright Minds Biosciences And 2 More Canadian Biotech Stocks
- Bright Minds Biosciences to Participate in the 2026 FPWR Research Symposium and PWS Family Conference
- What Makes Bright Minds Biosciences Inc. (DRUG) a Strong Momentum Stock: Buy Now?
- Wall Street Analysts See a 97.01% Upside in Bright Minds Biosciences Inc. (DRUG): Can the Stock Really Move This High?
- Wall Street Analysts See a 107.53% Upside in Bright Minds Biosciences Inc. (DRUG): Can the Stock Really Move This High?
- All You Need to Know About Bright Minds Biosciences Inc. (DRUG) Rating Upgrade to Strong Buy
- 3 Canadian Biotech Stocks Trading Up To 93% Below Fair Value
- Auxly Cannabis Group And 2 Other Canadian Biotech Stocks To Watch
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Bright Minds Biosciences Inc..
Full DRUG Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.